Corpus Intelligence IC Memo — SAINT FRANCIS HOSPITAL MUSKOGEE 2026-04-26 04:04 UTC
IC Memo — SAINT FRANCIS HOSPITAL MUSKOGEE
Investment Committee Memorandum | OK | 236 beds | Grade C | EBITDA uplift $14.5M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

SAINT FRANCIS HOSPITAL MUSKOGEE

CCN 370025 | MUSKOGEE, OK | 236 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

SAINT FRANCIS HOSPITAL MUSKOGEE is a 236-bed suburban community hospital in MUSKOGEE, OK with $196.5M in net patient revenue and a 11.6% operating margin. The hospital serves a payer mix of 36.0% Medicare, 26.8% Medicaid, and 37.2% commercial.

Thesis: Platform Growth. Our ML models identify $14.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 11.6% to 18.9% (+736bps).

Net Revenue HCRIS$196.5M
Current EBITDA COMPUTED$22.7M
Operating Margin COMPUTED11.6%
Occupancy HCRIS44.5%
Revenue / Bed COMPUTED$833K
Net-to-Gross HCRIS24.8%
Distress Probability ML55.8%

2. Market Context & Competitive Position

147
OK Hospitals
-8.8%
State Median Margin
15
Comparable Hospitals

OK has 147 Medicare-certified hospitals with a median operating margin of -8.8%. The target's margin of 11.6% places it above the state median. Among 15 size-comparable peers (118-472 beds), the median margin is -8.1%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (118-472), prioritizing same-state peers. 15 hospitals in the comp set.

HospitalStateBedsRevenueMargin
SAINT FRANCIS HOSPITAL MUSKOGE (Target)OK236$196.5M11.6%
ST ANTHONY HOSPITALOK430$711.2M-10.3%
MERCY HOSPITAL OKCOK344$674.3M10.5%
HILLCREST MEDICAL CENTEROK424$590.1M-3.3%
ST. JOHN MEDICAL CENTEROK419$547.8M-0.5%
NORMAN REGIONAL HOSPITAL AUTHOOK322$540.7M-8.1%
COMANCHE COUNTY MEMORIAL HOSPIOK201$304.2M-7.9%
INTEGRIS SOUTHWEST MEDICAL CENOK169$267.6M-13.5%
HILLCREST HOSPITAL SOUTHOK152$218.9M4.9%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $14.5M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$4.1M+210bp18mo
Cost to Collect4.5%2.5%$3.9M+200bp12mo
Denial Rate Reduction12.0%6.5%$3.9M+198bp12mo
A/R Days Reduction5200.0%3800.0%$2.4M+122bp9mo
Clean Claim Rate88.0%96.0%$126K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$4.1M
Cost to Collect
$3.9M
Denial Rate Reduction
$3.9M
A/R Days Reduction
$2.4M
Clean Claim Rate
$126K
Total EBITDA Uplift$14.5M
Current EBITDA$22.7M
+ RCM Uplift+$14.5M
Pro Forma EBITDA$37.2M
Current Margin11.6%
Pro Forma Margin18.9%
WC Released (1x)$7.5M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$35.0M$294.6M8.43x53.1%
Base (11x exit)10.0x11.0x$35.0M$335.4M9.59x57.2%
Bull Case9.0x11.0x$31.5M$394.5M12.54x65.8%
Bull (12x exit)9.0x12.0x$31.5M$439.6M13.97x69.5%
Bear Case11.0x10.0x$38.5M$210.9M5.48x40.5%
Bear (11x exit)11.0x11.0x$38.5M$244.4M6.36x44.8%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumElevated Medicaid exposure (26.8%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 55.8% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 15 hospitals with 118-472 beds
  • Same-state prioritization (n=16)
  • Comp margins: P25=-22.9% / P50=-8.1% / P75=-2.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.